Biogen response to letter re: Scottish Spinraza Access

Following, the SMA partner organisations collective letter to Biogen management to request a review of pricing and resubmission to The Scottish Medicines Consortium, in order to enable further progress and access to Spinraza for SMA Types 2 and 3, this response was received.


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.